These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 5326963)
1. The mechanism in inhibition of ovulation in oral contraception. I. The excretion of total pituitary gonadotrophins in fertile, menopausal, and oophorectomized women during treatment with 6-methyl-6-dehydro-17-alpha-acetoxyprogesterone+ 17-alpha-ethynyl-oestradiol-3-methylether. Starup J Acta Endocrinol (Copenh); 1966 Mar; 51(3):469-80. PubMed ID: 5326963 [No Abstract] [Full Text] [Related]
2. Excretion of gonadotrophins during gestagen- and oestrogen-treatment. The excretion of total pituitary gonadotrophins in menopausal and oophorectomized women during treatment with 6-methyl-6-dehydro-17-alpha-acetoxyprogesterone and 17-alpha-ethynyl-oestradiol-3-methylether respectively. Starup J Acta Endocrinol (Copenh); 1967 Apr; 54(4):637-44. PubMed ID: 6071486 [No Abstract] [Full Text] [Related]
3. The mechanism in inhibition of ovulation in oral contraception. 3. The excretion of total pituitary gonadotrophins and luteinizing hormone in fertile women during cyclical treatment with 6-methyl-6-dehydro-17-alpha-acetoxyprogesterone together with 17-alpha-ethynyl-oestradinol-3-methylether. Starup J; Lebech PE Acta Endocrinol (Copenh); 1967 Oct; 56(2):188-96. PubMed ID: 6072686 [No Abstract] [Full Text] [Related]
4. The mechanism in inhibition of ovulation in oral contraception. II. The effect of PMS and HCG observed at laparotomy in patients treated with 6-methyl-6-dehydro-17-alpha-acetoxyprogesterone ogether with 17-alpha-ethynyl-oestradiol-3-methylether. Starup J; Ostergaard E Acta Endocrinol (Copenh); 1966 Jun; 52(2):292-304. PubMed ID: 5952708 [No Abstract] [Full Text] [Related]
5. Occurrence and function of corpora lutea during different forms of oral contraception. Ostergaard E; Starup J Acta Endocrinol (Copenh); 1968 Mar; 57(3):386-94. PubMed ID: 5694273 [No Abstract] [Full Text] [Related]
6. THE EFFECT OF GONADOTROPHINS OBSERVED AT LAPAROTOMY IN PATIENTS TREATED WITH 6-DEHYDRO-6-METHYL-17-ACETOXY-PROGESTERONE (DMAP)+ETHINYL-ESTRADIOL-3-METHYLETHER (EE3ME) FOR INHIBITION OF THE OVULATION. STARUP J; OSTERGAARD E Acta Obstet Gynecol Scand; 1965; 43():SUPPL 7:40-1. PubMed ID: 14286744 [No Abstract] [Full Text] [Related]
7. [Is there a false positive pregnancy tests after administration of "ovulation inhibitors"?]. Soost HJ; Zech G Med Klin; 1966 Sep; 61(38):1494-5. PubMed ID: 5998597 [No Abstract] [Full Text] [Related]
8. [Clinical study of a new ovulation inhibitor]. Lecart C Schweiz Rundsch Med Prax; 1970 Jun; 59(25):933-6. PubMed ID: 5513424 [No Abstract] [Full Text] [Related]
9. [Biogest]. Melich H Cas Lek Cesk; 1972 Jul; 111(30):694-5. PubMed ID: 5079918 [No Abstract] [Full Text] [Related]
10. Postponement of menses, suppression of urinary gonadotrophins, 17-KGS and 17-KS in normal women treated with a megestrol acetate/mestranol combination (delpregnin) from day 20 of the cycle. Ostergaard E; Arends J; Hamburger C; Johnsen SG Acta Endocrinol (Copenh); 1966 Sep; 53(1):13-23. PubMed ID: 4225011 [No Abstract] [Full Text] [Related]
11. [Influence of the structure of steroids on their antiovulatory, antigonadotropic, and progestative activity]. Jayle MF Therapie; 1968; 23(2):201-21. PubMed ID: 5701506 [No Abstract] [Full Text] [Related]
12. [Does the cyclic treatment with ovulation inhibitors produce pseudopregnancy?]. Siegel P Gynaecologia; 1966; 161(2):151-4. PubMed ID: 5925685 [No Abstract] [Full Text] [Related]
13. [Clinical experience with hormonal suppression of ovulation using the sequential method with chlormadinone acetate and mestranol in different dosage]. Heinen G Med Welt; 1969 Nov; 44():2420-6. PubMed ID: 5374595 [TBL] [Abstract][Full Text] [Related]
14. INHIBITION OF OVULATION OBSERVED AT LAPAROTOMY IN PATIENTS TREATED WITH 6-DEHYDRO-6-METHYL-17-ALPHA-ACETOXYPROGESTERONE (DMAP). OSTERGAARD E Int J Fertil; 1964; 9():25-8. PubMed ID: 14106264 [No Abstract] [Full Text] [Related]
15. [Clinical experiences with Ovosiston for inhibition of ovulation]. Kühne D Dtsch Gesundheitsw; 1966 Feb; 21(8):377-9. PubMed ID: 4165201 [No Abstract] [Full Text] [Related]
16. Comparative studies of the ethynyl estrogens used in oral contraceptives. II. Antiovulatory potency. Goldzieher JW; Pena A; Chenault CB; Woutersz TB Am J Obstet Gynecol; 1975 Jul; 122(5):619-24. PubMed ID: 1146927 [TBL] [Abstract][Full Text] [Related]
17. [Behavior of serum copper and iron under the influence of the ovulation inhibitor Ovosiston]. Methfessel HD; Mlytz H; Methfessel G; Löffler F Z Gesamte Inn Med; 1969 Oct; 24(19):659-61. PubMed ID: 4188438 [No Abstract] [Full Text] [Related]
18. [Luteolytic agents and reproduction]. Cortés-Gallegos V Gac Med Mex; 1973 Oct; 106(4):259-86. PubMed ID: 4593968 [No Abstract] [Full Text] [Related]
19. [Blood glucose in women on Noracycline and Gestranol]. Jabloński K; Giermańska T; Filc-Bauer A Pol Tyg Lek; 1972 Oct; 27(43):1676-8. PubMed ID: 4639621 [No Abstract] [Full Text] [Related]
20. Pituitary-adrenal function in oral contraception. Starup J; Sele V; Buus O Acta Endocrinol (Copenh); 1966 Sep; 53(1):1-12. PubMed ID: 4289353 [No Abstract] [Full Text] [Related] [Next] [New Search]